Health

CNN Chief Medical Correspondent Sanjay Gupta and CNN Medical Analyst Dr. Leana Wen weigh in on the timeline of President Joe Biden testing positive for Covid-19.

A data-driven wellness solution with fatigue monitoring capabilities using scheduling insights enables law enforcement agencies to take a proactive approach to officer health and well-being.

…

DoD and VA Healthcare Facilities Can Now Purchase UroViu’s Single-Use Endoscopy Products

LOS ALTOS, Calif. – October 13, 2022 – (Newswire.com)

UroViu Corp, a company that develops and commercializes highly portable single-use endoscopy platforms, announced today that it has been added to the US Defense Logistics Agency’s Medical Equipment ECAT. With a contract secured through Fidelis Sustainability Distribution, Veterans will now have access to the latest endoscopy products on the market. 

Under the agreement, UroViu will sell its entire product line at a contracted price for distribution exclusively through Fidelis to over 1,200 VA and DOD healthcare facilities throughout the United States that serve 9 million enrolled Veterans each year. 

“Urology is the second most common indication by procedure volume in the Veterans Health Administration (VHA) representing a large market for UroViu,” said Sebastien Cadet, Chief Commercial Officer of UroViu Corp. “ECAT is the most convenient and cost-effective way to deliver our products to all government facilities. It is with great pride we can now efficiently support our Veterans.”

Single-use endoscopy is a safer and more reliable alternative to traditional reusable scopes which must be cleaned, disinfected, and sanitized after every use. The difficulty of servicing traditional scopes has led to FDA scrutiny due to cross-contamination risks. UroViu’s single-use scopes eliminate those risks. The single-use platform ranges from a 12-Fr diagnostic semi-rigid cystoscope and equivalent hysteroscope, a 14-Fr injection cystoscope with an integrated needle for drug delivery, to a flexible, deflectable, and rotatable 16.5-Fr cystoscope have the potential to help any government facilities improve care and efficiency. 

“Fidelis’ SDVDSB status provides UroViu with preferential access to secure VHA and DOD contracts,” said Joel Kohn, President of Fidelis Sustainability Distribution, LLC. “More importantly, we help streamline the procurement process thus accelerating the delivery of cutting-edge technologies such as UroViu’s single-use endoscopes that our Veterans deserve.”

About UroViu Corporation

UroViu Corporation’s mission is to revolutionize the endoscopy platform for improved patient care and provider efficiency with operations in California and Washington and production facilities in Asia. UroViu is the developer of the always-ready cystoscopy & hysteroscopy platforms, the highly portable, self-contained, and versatile single-use endoscopy solution to meet the needs of Urologists, UroGynecologists, and Gynecologists. The unique portable platform and product suite are protected by a portfolio of 20+ patents granted worldwide and many more pending patents. UroViu’s vision is to simplify the scope of patient care. For more information please visit www.uroviu.com.

About Fidelis Sustainability Distribution

Fidelis Sustainability Distribution, LLC, (FSD) is a Nevada-based, Service-Disabled Veteran-Owned Small Business (SDVOSB) focused on helping streamline the acquisition of medical/dental technology in US Government facilities. Our firsthand industry experience of how technology moves from concept to commercialization and through healthcare supply chains enables us to support our manufacturing partners and Government customers alike at the highest level. Since 2014, FSD has secured over $80M+ in positive past performance and is dedicated to serving all major Federal Healthcare facilities including 170+ VAMC’s, 1,000+ CBOC’s,150+ DOD Medical Facilities, and Health and Human Services (HHS).

Contact Information:

Lisa Sorbo

Marketing Manager, UroViu Corp
[email protected]

941-667-0043

Press Release Service
by
Newswire.com

Original Source:

UroViu Corp Secures Medical Equipment ECAT Contract for VA DoD Purchasing

Dr. Andrea Small-Howard discusses the company’s novel process for developing disease-specific, cannabinoid-based therapeutics.

LAS VEGAS – October 13, 2022 – (Newswire.com)

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating the potential efficacy of their proprietary cannabis-inspired mixtures today at the Canna Pharma 2022 Conference in San Diego, California. Dr. Small-Howard explains Gb Sciences’ novel process for developing disease-specific, cannabinoid therapeutics in her presentation entitled “Case Studies: Identification of Minimum Essential Therapeutic Mixtures from Cannabis Plant Extracts by Screening in Cell and Animal Models.” Gb Sciences’ case studies include scientific evidence demonstrating the potential efficacy of their cannabinoid-based therapeutic mixtures designed to treat Parkinson’s disease, chronic pain, or inflammation using their novel minimal essential mixture approach.

“Medicinal cannabis has shown great promise for the symptomatic treatment of many serious human disorders, but concerns around safety, consistency, legality, psychoactivity, and non-standardized routes of delivery, such as smoking and vaping, have slowed the adoption of the use of medical cannabis within traditional, physician-guided patient treatment programs. To address these challenges, we hypothesized that within Cannabis plant extracts, there would be a minimal essential mixture of compounds that preserves whole plant benefits, but with the manufacturing, quality control, and regulatory benefits of single ingredient therapies,” said Dr. Andrea Small-Howard.

Minimal essential mixtures (MEM) is a term Gb Sciences has coined from their proprietary research after deeming that a simplified mixture represented a happy medium between whole plant medicines and single ingredient drugs. Minimum Essential Mixtures are designed to retain increased therapeutic effectiveness from molecular synergies within the original plant extracts, but with the manufacturing efficiencies, quality assurances, and regulatory advantages of single ingredient drugs. Gb Sciences’ disease-specific MEM are produced for clinical evaluation using synthetic homologs of cannabis-based ingredients incorporated into sophisticated oral delivery modalities including Oral Dissolving Tablets (ODT), Oral Thin Films (OTF), time-released oral nanoparticles, and gel capsules to increase the stability, bioavailability, and ease-of-use of these ingredients relative to the non-standardized delivery methods used for Cannabis plant extracts.

Gb Sciences was recently published in Pharma’s Almanac discussing the strategy behind their plant-inspired minimum essential mixtures, which provides context for the case studies being presented today.

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. 

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

Madeleine Moench
[email protected]

Press Release Service
by
Newswire.com

Original Source:

TODAY: Gb Sciences’ President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference

A recent study published in the journal Environment International found plastic particles in blood samples in 80% of people tested. The effects of microplastics in the body aren’t known – but researchers said the new results areconcerning and that microplastics could damage human cells. Neil and Roy look at the vocabulary used in the headlines […]

Will Be the Only Provider in King County Awarded the Competitive Grant

TUKWILA, Wash. – October 12, 2022…

Affiliation marks continued growth for Great Expressions in the Northeast

SOUTHFIELD, Mich. – October 12…